Objective: This systematic review and meta-analysis were performed to evaluate the efficacy of preoperative dutasteride treatment for reducing surgical blood loss in patients undergoing transurethral resection of the prostate (TURP). Methods: A systematic search was performed from the electronic databases including PubMed, EMBASE, and Cochrane Library by May 2016. We followed the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analysis statement when examining the literature. Identified articles were strictly appraised for quality and relevance. Results: Five randomized controlled trials (RCTs) and 5 retrospective cohort studies involving 1,022 patients with benign prostate hyperplasia were analyzed based on the inclusion criteria. Pooled analysis revealed that preoperative treatment with dutasteride had a significantly smaller decrease in hemoglobin (weighted mean difference [WMD] -0.47, 95% CI -0.70 to -0.24, p < 0.0001) and hematocrit levels (WMD -1.03, 95% CI -1.73 to -0.33, p = 0.004); However, no significant difference has been found in terms of the total blood loss during TURP and blood loos per gram of resected prostatic tissue, the weight of resected prostate tissue, the microvessel density of the prostate, and the transfusion rate between the dutasteride and the control group. Conclusions: This systematic review and meta-analysis indicate that preoperative treatment with dutasteride could reduce surgical bleeding during TURP, but the findings of this study should be further confirmed by well-designed prospective RCTs with a larger patient series.

Keywords:
Benign prostatic hyperplasia, Transurethral resection of the prostate, Intraoperative blood loss, Dutasteride, Meta-analysis
1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
2.
Gravas S, Bachmann A, Descazeaud A, et al: Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), Incl. Benign Prostatic Obstruction (BHO). Presented at 30th Annual EAU Congress, Madrid, Spain, March 20-24, 2015.
3.
Rassweiler J, Teber D, Kuntz R, Hofmann R: Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol 2006;50:969-979; discussion 980.
4.
Delakas D, Lianos E, Karyotis I, Cranidis A: Finasteride: a long-term follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001;67:69-72.
5.
Lekas AG, Lazaris AC, Chrisofos M, Papatsoris AG, Lappas D, Patsouris E, Deliveliotis C: Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology 2006;68:436-441.
6.
Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC: Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol 2002;168:2024-2026.
7.
Berardinis ED, Antonini G, Busetto GM, Gentile V, Silverio FD: Reducedintraoperative bleeding during transurethral resection of the prostate: evaluation offinasteride, vascular endothelial growth factor, and CD34. Curr Prostate Rep 2005;6:123-127.
8.
Liu XD, Yang YR, Lu YP, Zhang XH, Li FY, Zhang XH, Li FY, Wei Q, Li H, Shi M, Chen ZF: Preoperative finasteride on decreasing operative bleeding during transurethral resection of prostate. Chin J Urol 2003;24:694-696.
9.
Lekas AG, Lazaris AC, Chrisofos M, Papatsoris AG, Lappas D, Patsouris E, Deliveliotis C: Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology 2006;68:436-441.
10.
Li GH, He ZF, Yu DM, Li XD, Chen ZD: [Effect of finasteride on intraoperative bleeding and irrigating fluid absorption during transurethral resection of prostate: a quantitative study]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004;33:258-260.
11.
Zong HT, Peng XX, Yang CC, Zhang Y: A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia. Asian J Androl 2011;13:812-818.
12.
Zhu YP, Dai B, Zhang HL, Shi GH, Ye DW: Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol 2015;15:47.
13.
Marberger M. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol 2006;3:495-503.
14.
Hahn RG, Fagerström T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A, Morrill B: Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int 2007;99:587-594.
15.
Boccon-Gibod L, Valton M, Ibrahim H, Boccon-Gibod L, Comenducci A: [Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate]. Prog Urol 2005;15:1085-1089.
16.
Pastore AL, Mariani S, Barrese F, Palleschi G, Valentini AM, Pacini L, Petrozza V, Carbone A, Cappa M: Transurethral resection of prostate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss. J Endourol 2013;27:68-70.
17.
Bepple JL, Barone BB, Eure G: The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial). Urology 2009;74:1101-1104.
18.
Phillips B, Ball C, Sackett D, et al: Oxford Centre for Evidence-based Medicine - Levels of Evidence. 2009. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidencemarch-2009/ (accessed May 2016).
19.
Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D, Laupacis A: Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trial 1999;20:448-452.
20.
Wells GA, Shea B, O'Connell, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Metaanalyses. Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed May 2016).
21.
Busetto GM, Giovannone R, Gentile V, Antonini G, De Berardinis E: Dutasteride can reduce intraoperative bleeding during transurethral resection of the prostate: evaluation of vascular endothelial growth factor (VEGF) and CD34. Urol Suppl 2014;13:e237-e237.
22.
Tuncel A, Ener K, Han O, Nalcacioglu V, Aydin O, Seckin S, Atan A: Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. Scand J Urol Nephrol 2009;43:377-382.
23.
Zaitsu M, Tonooka A, Mikami K, Hattori M, Takeshima Y, Uekusa T, Takeuchi T: A dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia. ISRN Urol 2013;2013:863489.
24.
Arratia-Maqueo JA, Garza-Cortés R, Gómez-Guerra LS, Cortés-González JR: [Effect of one month treatment with dutasteride on transurethral resection of the prostate]. Actas Urol Esp 2010;34:866-869.
25.
Busetto GM, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S, Ragonesi G, Gentile V, De Berardinis E: Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int 2015;116:117-123.
26.
Woo JH, Kang JY, Kim EK, Yoo TK: The effect of short term dutasteride therapy on microvessel density in benign prostatic hyperplasia. Korean J Urol 2008;49:515-519.
27.
Kim KS, Jeong WS, Park SY, Kim YT, Moon HS: The effect of two weeks of treatment with dutasteride on bleeding after transurethral resection of the prostate. World J Mens Health 2015;33:14-19.
28.
Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
29.
Kravchick S, Cytron S, Mamonov A, Peled R, Linov L: Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology 2009;73:1274-1278.
30.
Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, Fracchia JA: The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169:20-23.
31.
Das K, Lorena PD, Ng LK, Lim D, Shen L, Siow WY, Teh M, Reichardt JK, Salto-Tellez M: Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer 2010;17:757-770.
32.
Andriole GL, Humphrey P, Ray P, et al: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172:915-919.
33.
Canda AE, Mungan MU, Yilmaz O, Yorukoglu K, Tuzel E, Kirkali Z: Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol 2006;38:275-280.
34.
Donohue JF, Barber NJ: How do we investigate haematuria and what role has finasteride? BJU Int 2004;93:3-4.
35.
Choi JD, Kim JH, Ahn SH: Transitional zone index as a predictor of the efficacy of α-blocker and 5α-reductase inhibitor combination therapy in Korean patients with benign prostatic hyperplasia. Urol Int 2016;96:406-412.
36.
Yin L, Teng J, Huang CJ, Zhang X, Xu D: Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol 2013;27:604-611.
37.
Thangasamy IA, Chalasani V, Bachmann A, Woo HH: Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol 2012;62:315-323.
38.
Omar MI, Lam TB, Alexander CE, Graham J, Mamoulakis C, Imamura M, Maclennan S, Stewart F, N'dow J: Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU Int 2014;113:24-35.
39.
Gabr AH, Gabr MF, Elmohamady BN, Ahmed AF: Prostatic artery embolization: a promising technique in the treatment of high-risk patients with benign prostatic hyperplasia. Urol Int 2016;97:320-324.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.